FY2029 Earnings Estimate for PepGen Issued By HC Wainwright

PepGen Inc. (NASDAQ:PEPG) – Investment analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of PepGen in a report issued on Thursday, January 30th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.21) for the year. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share.

Other research analysts have also recently issued research reports about the company. Wedbush cut their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Bank of America cut PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a research note on Monday, December 16th.

PepGen Stock Performance

Shares of NASDAQ PEPG opened at $1.44 on Friday. The stock’s 50 day moving average price is $3.83 and its 200-day moving average price is $7.50. PepGen has a twelve month low of $1.42 and a twelve month high of $19.30.

PepGen (NASDAQ:PEPG) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.21.

Hedge Funds Weigh In On PepGen

Several institutional investors have recently bought and sold shares of the company. Point72 DIFC Ltd bought a new stake in shares of PepGen in the second quarter valued at $42,000. China Universal Asset Management Co. Ltd. purchased a new stake in PepGen in the 4th quarter worth about $26,000. Allspring Global Investments Holdings LLC bought a new stake in PepGen in the 3rd quarter valued at about $95,000. Renaissance Technologies LLC purchased a new stake in PepGen during the second quarter valued at about $192,000. Finally, Marshall Wace LLP bought a new position in PepGen during the second quarter worth about $196,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.